Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunoloġiċi għall-felini, - qtates - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. Ġew murija onsets ta 'immunità 1 ġimgħa wara l-kors ta' tilqim primarju għal rinotrakeite, kaliċivirus u komponenti ta 'chlamydophila felis. it-tul ta 'l-immunità huwa ta' sena wara l-aħħar vaċċinazzjoni (mill-ġdid).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunoloġiċi għall-felini, - qtates - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunoloġiċi għall-felini, - qtates - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. Ġew murija onsets ta 'immunità ġimgħa wara l-kors ta' tilqim primarju għal rinotrakeite, kaliċivirus, chlamydophila felis u komponenti panleucopenia. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunoloġiċi għall-felini, - qtates - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunoloġiċi għall-felini, - qtates - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

virbac s.a. - purified p45 feline leukaemia virus envelope antigen, live feline calicivirus (strain f9), live feline viral rhinotracheitis virus (strain f2), live feline panleucopenia virus - ħajjin tal-virus tal-panlewkopenja fil-qtates / parvovirus + ħajjin-feline rhinotracheitis virus + jgħixu kaliċivirus fil-qtates + inattivat feline leukaemia virus - qtates - għal immunizzazzjoni attiva ta 'qtates minn tmien ġimgħat kontra: calicivirosis qtates biex jitnaqqsu sinjali kliniċi. rhinotracheitis virali tal-qtates biex jitnaqqsu s-sinjali kliniċi u l-eskrezzjoni virali. panleucopenia qtates biex tevita l-lewkopenija u biex tnaqqas is-sinjali kliniċi. lewkimja tal-qtates biex tevita viremija persistenti u sinjali kliniċi tal-marda relatata. il-bidu tal-immunità: 3 ġimgħat wara l-vaċċinazzjoni primarja għall-komponenti tal-panleukopenja u tal-lewkimja, u 4 ġimgħat wara l-vaċċinazzjoni primarja għall-komponenti tal-virus tal-calicivirus u r-rinotrakeite. tul ta 'żmien ta' l-immunità: sena wara t-tilqima primarja għall-komponenti kollha.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunoloġiċi għall-felini, - qtates - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

medimmune llc - reassortant-virus tal-influwenza (ħaj attenwat) tar-razez li ġejjin:/california/7/2009 (h1n1)pdm09 bħal strejn, a/victoria/361/2011 (h3n2) like strain, b/massachusetts/2/2012 like strain - influenza, human; immunization - vaċċini - profilassi ta 'l-influwenza f'individwi ta' 24 xahar sa inqas minn 18-il sena. l-użu ta fluenz għandu jkun ibbażat fuq rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - virus ta 'l-influwenza li jassorbi mill-ġdid (ħaj attenwat) tar-razza li ġejja: razza a / vietnam / 1203/2004 (h5n1) - influwenza, bniedem - vaċċini - profilassi tal-influwenza f'sitwazzjoni pandemika ddikjarata uffiċjalment fit-tfal u fl-adolexxenti minn 12-il xahar sa inqas minn 18-il sena. l-influwenza pandemika-vaċċin h5n1 astrazeneca għandu jintuża skont il-gwida uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

zoetis belgium sa - klieb distemper virus, razza cdv bio 11/a, klieb adenovirus tat-tip 2, razza cav-2 bio 13, klieb parvovirus tip 2b, razza cpv-2b bio 12/b u l-klieb parainfluenza tat-tip 2 virus, razza cpiv-2 bio 15 (kollha ħaj attenwat) - immunoloġiċi għall-canidae, vaċċini virali Ħajjin - klieb - immunizzazzjoni attiva ta 'klieb minn sitt ġimgħat. biex tipprevjeni l-mortalità u sinjali kliniċi ikkawżati mill-klieb distemper virus,biex jimpedixxi l-mortalità u sinjali kliniċi ikkawżati mill-klieb adenovirus tat-tip 1,li jipprevjenu l-sinjali kliniċi u l-eskrezzjoni virali kkawżata mill-klieb adenovirus tat-tip 2,għall-prevenzjoni ta ' sinjali kliniċi, lewkopenija u l-eskrezzjoni virali kkawżata mill-klieb parvovirus,għall-prevenzjoni tal-sinjali kliniċi u l-eskrezzjoni virali kkawżata mill-klieb parainfluenza virus.